Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma

Inclusion Criteria: * ECOG performance status 0 or 1 * Estimated life expectancy of greater than 6 months * Greater than or equal to 4 weeks from chemotherapy, radiotherapy, immunotherapy, or systemic glucocorticoid therapy * Greater than or equal to 6 months from prior bone marrow or peripheral blood stem cell (PBSC) transplant * Histologically confirmed alveolar soft part sarcoma or clear cell sarcoma at any age. * Evidence of metastatic disease, including having spread either to distant sites that may include brain metastases, or to regional lymph nodes alone, or locally advanced primary lesion that is not fully surgically resectable at study entry. * Histologically confirmed Stage IV renal cell carcinoma (patients with brain metastases still eligible) * Any patients with Stage IV renal cell carcinoma under the age of 25 years who do not have a renal cell carcinoma predisposition syndrome * Patients with Stage IV melanoma and under the age of 18 years Exclusion Criteria: * Uncontrolled active infection * Pregnancy or nursing mothers * Infection with HIV, hepatitis B or hepatitis C * Any other significant medical, surgical, or psychiatric condition that may interfere with compliance with protocol regimen * Other current malignancies apart from any in situ cancer or basal or squamous cell carcinoma * Pediatric melanoma only: infants with transplacentally acquired melanoma; or children with brain metastases and malignant melanoma.